Menu
Introducing Orlance MACH-1®
LOW-DOSE, HIGHLY SCALABLE POWDERED NUCLEIC ACID VACCINES WITHOUT COLD CHAIN REQUIREMENTS.
Orlance, Inc., headquartered in Seattle, WA, is developing its MACH-1® platform to deliver nucleic acid vaccines and related therapies without cold chain restrictions. Leveraging $9.6M in NIH SBIR funding, Orlance has developed the MACH-1 platform to intradermally deliver stable, powdered vaccines in a needle-free manner that minimizes dose size, eliminates cold chain requirements, and is poised to increase access and compliance. The company’s executive team comprises significant immunology, vaccinology, biotech development, bioengineering, regulatory, and partnering experience and is well poised to bring its preclinical assets to IND and Phase 1 readiness in 2022.
Meet Us At:
Boston Biotech Week, Sept 20-23, 2021
World Vaccine Congress Europe, Oct 19-21, 2021
Our Team
Orlance, inc
Kris Aalto, CEO
25 years of bioengineering, innovation development, regulatory and clinical affairs, product launch, VC and executive experience.
Deb Fuller, PhD, CTO
Co-inventor of MACH-1 technology, formerly at PowderJect, UW Professor, the lab focuses on NA vaccines for multiple pathogens.
Jim Mullins, PhD
Co-founder and SAB member, UW, molecular and computational approaches vaccine design, the originator of conserved element (CE) approach to vaccine development.
Ken Bagley, PhD
DIR. R&D 15 years in NA vaccine field, developed genetic adjuvant platform at Profectus Biosciences, Inc.
Hannah Frizzell, PhD
Bioengineer, Immunology, and nano delivery system experience.
Lyuda Lebedinski
Administrative and
Financial Manager
Amanda Woodcock
Mechanical Engineer
Jonathan Aalto
Research Technician
IF YOU’RE A POTENTIAL PARTNER
Series A or government funding for Phase 1/2a Orlance MACH-1® influenza or CoV vaccine
DNA and mRNA vaccine Phase 1 candidates
